logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2020 — Tackling health-related QoL mCRC after first-line immunotherapy

Pembrolizumab significantly improves health-related QoL vs standard of care in a patient subgroup.